Open access · US-GOV via ClinicalTrials.gov Clinical trial

Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease

Authors not listed

Indiana University · 2019

Dysbiosis Human Randomized controlled trial

Abstract

This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-05-31 MST

Cite this

APA

Anonymous. (2019). Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease. <em>Indiana University</em>. https://clinicaltrials.gov/study/NCT04121858

Vancouver

Anonymous. Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease. Indiana University. 2019.

BibTeX

@misc{anon2019BrainS, title = {Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease}, author = {Anonymous}, journal = {Indiana University}, year = {2019}, }